Daily Cosmetic Research Analysis
Three papers advance cosmetic safety and methodology: (1) mechanistic evidence that zinc oxide nanoparticles perturb lipid metabolism via the SIRT1–FOXO3–ACBD5 axis, (2) a PBPK framework that accurately emulates IVPT for sunscreen actives to inform MUsT design, and (3) a critical appraisal showing high-content, semi-automated NAMs outperform traditional FISH/CREST for identifying aneugens. Together, they strengthen regulatory science and reduce trial-and-error and animal testing.
Summary
Three papers advance cosmetic safety and methodology: (1) mechanistic evidence that zinc oxide nanoparticles perturb lipid metabolism via the SIRT1–FOXO3–ACBD5 axis, (2) a PBPK framework that accurately emulates IVPT for sunscreen actives to inform MUsT design, and (3) a critical appraisal showing high-content, semi-automated NAMs outperform traditional FISH/CREST for identifying aneugens. Together, they strengthen regulatory science and reduce trial-and-error and animal testing.
Research Themes
- Nanomaterial safety in cosmetics
- Model-based dermal absorption assessment
- Next-generation genotoxicity testing for cosmetic ingredients
Selected Articles
1. Zinc oxide nanoparticles disrupt peroxisome-endoplasmic reticulum contacts and increase very-long-chain fatty acid content.
In vivo and in vitro models show that ZnO nanoparticles elevate hepatic VLCFAs and disrupt peroxisomal β-oxidation and Po-ER contacts by downregulating ACBD5 through the SIRT1–FOXO3 axis. These mechanistic data raise safety considerations for ZnO-containing topical products that could alter systemic lipid homeostasis upon exposure.
Impact: Identifies a previously unrecognized SIRT1–FOXO3–ACBD5 pathway by which ZnO nanoparticles perturb lipid metabolism, directly informing risk assessment of widely used sunscreen ingredients.
Clinical Implications: Safety dossiers for ZnO-based sunscreens should consider biomarkers of peroxisomal function (e.g., ACBD5) and systemic lipid endpoints; formulations minimizing systemic exposure and post-market surveillance for lipid disturbances may be warranted.
Key Findings
- ZnO nanoparticles increased hepatic VLCFAs, triglycerides, and total cholesterol after 10 weeks in vivo.
- Peroxisomal β-oxidation and peroxisome–ER contacts were reduced in vivo and in hepatocyte cultures.
- ZnO nanoparticles downregulated ACBD5; overexpression rescued and knockdown mimicked the phenotype.
- FOXO3 directly regulates ACBD5; ZnO nanoparticles increased acetylation, inhibited FOXO3 nuclear entry, and reduced SIRT1, implicating SIRT1-mediated FOXO3 deacetylation (K243).
Methodological Strengths
- Integrated in vivo and in vitro systems with genetic perturbations (overexpression/knockdown) to establish causality.
- Mapped a mechanistic signaling axis (SIRT1–FOXO3–ACBD5) linking nanoparticle exposure to organelle contacts and lipid metabolism.
Limitations
- Primary animal model is fish; human relevance and dermal exposure scenarios were not directly tested.
- Single dietary dose (10 mg/kg) and 10-week duration limit dose–response and long-term risk characterization.
Future Directions: Validate the SIRT1–FOXO3–ACBD5 signature in mammalian skin and systemic tissues under dermal ZnO exposure, and incorporate these biomarkers into cosmetic safety assessments.
Very-long-chain fatty acids (VLCFAs) are vital for growth, development, and overall health. Zinc oxide nanoparticles (ZnO NPs), recognized for their high bioavailability and wide use in medicine and nutrition, have an unclear impact on lipid metabolism. This study explores how ZnO NPs impact VLCFA metabolism using yellow catfish (Pelteobagrus fulvidraco) as a model organism. In vivo, 240 yellow catfish were divided into a control group and a group fed 10 mg/kg ZnO NPs diet for 10 weeks. Administration of ZnO NPs significantly increased hepatic VLCFA content, accompanied by elevated triglyceride (TG) and total cholesterol (T-CHO) levels. Additionally, ZnO NPs reduced peroxisomal β-oxidation and peroxisome-ER (Po-ER) contacts. In vitro studies with yellow catfish hepatocytes confirmed these findings and explored the underlying mechanisms. ZnO NPs reduced Po-ER attachment and significantly decreased peroxisomal β-oxidation levels. ZnO NPs markedly decreased the expression and localization of ACBD5, a key protein involved in Po-ER interactions and VLCFA degradation. Overexpression of ACBD5 counteracted these effects, whereas knockdown mimicked them. Further experiments revealed that FOXO3 directly regulates ACBD5 by binding to its promoter. ZnO NPs increased the acetylation level of hepatocytes, inhibited the nuclear entry of FOXO3, and reduced the protein level of SIRT1. SIRT1 directly regulates FOXO3 deacetylation at lysine 243. Overall, ZnO NPs disrupt lipid homeostasis by downregulating ACBD5 via the SIRT1/FOXO3 axis, impairing peroxisomal function and Po-ER contacts. This study highlights the significance of the SIRT1 - FOXO3 - ACBD5 axis in managing VLCFA-related metabolic disorders.
2. Physiologically based pharmacokinetic modelling of in vitro skin permeation of sunscreen actives under various experimental conditions.
A PBPK framework emulating IVPT for avobenzone, octocrylene, and oxybenzone predicted receptor and skin retention amounts within twofold across formulations, doses, and skin types. The approach supports rational IVPT protocol design and interpretation, reducing trial-and-error and informing maximum usage trials for sunscreens.
Impact: Introduces a validated modeling workflow to optimize IVPT for sunscreen actives, aligning with FDA expectations and potentially reducing resource use and unnecessary human exposure in MUsTs.
Clinical Implications: Regulatory and industry teams can use PBPK models to pre-qualify formulations, select doses and skin models, and anticipate variability, streamlining development and safety assessment of topical sunscreens.
Key Findings
- Developed PBPK models for avobenzone, octocrylene, and oxybenzone under varying formulations, doses, and skin types.
- Predicted receptor cumulative amounts and skin retention within twofold of observed data.
- Captured experimental variability given adequate donor/replicate numbers and mass balance accounting, enabling better IVPT design.
Methodological Strengths
- Multi-compound, multi-condition validation with quantitative performance targets (within twofold).
- Combines bottom-up parameterization with scenario-specific optimizations, enhancing generalizability.
Limitations
- Validation limited to three UV filters and in vitro datasets; lacks direct human in vivo confirmation.
- Twofold accuracy may be insufficient for certain regulatory decisions or narrow therapeutic indices.
Future Directions: Expand external validation across more UV filters and formulations, link IVPT-PBPK outputs to MUsT systemic exposure predictions, and develop decision frameworks for regulatory acceptance.
In vitro permeation testing (IVPT) is widely used in pharmaceutical and cosmetic formulation design and in safety assessment of topical products. The U.S. FDA recommends IVPT to screen sunscreen formulations prior to conducting a maximum usage trial (MUsT). For potential permeants such as highly lipophilic UV filters, designing IVPT protocols is a time- and resource-intensive trial-and-error process. Frequently used in clinical pharmacokinetics, physiologically based pharmacokinetic (PBPK) models can also emulate IVPT experiments. We present a PBPK modelling framework simulating the in vitro skin absorption of avobenzone, octocrylene, and oxybenzone investigated using different formulations, applied doses, and skin types. Combining bottom-up parameter predictions with optimizations relevant to changing experimental conditions, the models predict observed receptor cumulative and skin retention amounts within 2-fold and recover the variability obtained in experiments featuring suitable donor/replicate numbers and mass balances. The framework presented herein paves the way for greater integration of PBPK modelling into the design and interpretation of IVPT experiments and, ultimately, towards the design of MUsTs.
3. Critical Evaluation of Methods for the Identification of Aneugens.
This methodological review with comparative data shows that semi-automated NAMs (flow cytometry, high-content imaging) can robustly distinguish aneugens from clastogens and provide mechanistic insights, outperforming traditional FISH/CREST workflows. It outlines how NAMs can optimize in vivo genotoxicity study design and support margin-of-exposure derivations for regulatory safety assessments.
Impact: Provides an industry-relevant roadmap for replacing or augmenting legacy cytogenetic assays with high-throughput NAMs, improving mechanistic resolution and reducing time-to-decision for cosmetic ingredient safety.
Clinical Implications: Adoption of NAMs can streamline preclinical genotoxicity packages for cosmetic ingredients, reduce animal testing, and enable mechanism-informed points of departure to support margins of exposure.
Key Findings
- SWOT analysis highlighted strengths of NAMs (throughput, turnaround, mechanistic information) versus traditional FISH/CREST.
- Comparative data using reference aneugens (colchicine, taxol, AMG900) and clastogens (mitomycin C, MMS) illustrated method performance in distinguishing modes of action.
- High-content, semi-automated approaches were considered preferable for informing in vivo study design and deriving points of departure for margin-of-exposure estimates.
Methodological Strengths
- Cross-technique comparison anchored by reference compounds enhances external validity.
- Structured SWOT framework clarifies practical trade-offs and implementation opportunities.
Limitations
- Narrative/critical evaluation rather than PRISMA-compliant systematic review; potential selection bias.
- Primarily in vitro mammalian cell data; limited interlaboratory reproducibility and in vivo translation discussed.
Future Directions: Develop harmonized protocols and performance standards for high-content NAMs, and conduct interlaboratory ring trials linking NAM readouts to in vivo outcomes.
The genotoxic potential of chemicals must be evaluated in regulatory safety assessment settings, including but not limited to, the development of new pharmaceuticals, industrial chemicals, food and cosmetic ingredients, and agrochemicals. Initial assessment of the chromosome-damaging potential of chemicals is often conducted in mammalian cells using the micronucleus (MN) assay, a method capable of detecting both aneugenicity and clastogenicity. When differentiation between these modes of action (MOAs) is necessary, microscopy-based analyses using fluorescent In Situ Hybridization (FISH) or CREST staining have traditionally been employed. More recently, semi-automated in vitro new approach methods (NAMs), which leverage technologies like flow cytometry and high-content imaging, have increasingly been used across sectors due to their higher throughput and faster turnaround times. A SWOT (strengths, weaknesses, opportunities, and threats) analysis was conducted to systematically evaluate the merits and limitations of widely used NAMs in industry, with a focus on the pharmaceutical sector. Data from cultured mammalian cells exposed to reference aneugens (colchicine, taxol, and AMG900) and DNA-reactive clastogens (mitomycin C and methyl methanesulfonate) across methodologies are presented to illustrate the process of distinguishing aneugens from clastogens for the different techniques described herein. Collectively, these analyses highlight the capabilities of NAMs to distinguish aneugens from clastogens. The newer, high information content, semi-automated approaches were considered preferable to traditional microscopy-based FISH and CREST techniques as they provide insight into molecular mechanisms of aneugenicity and help optimize the design of future in vivo genotoxicity studies to facilitate deriving points of departure which may contribute to margin of exposure estimates.